Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.

Haupts, Stefan; Ledergerber, Bruno; Böni, Jörg; Schüpbach, Jörg; Kronenberg, Andreas; Opravil, Milos; Flepp, Markus; Speck, Roberto F; Grube, Christina; Rentsch, Katharina; Weber, Rainer; Günthard, Huldrych F (2003). Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. Antiviral therapy, 8(5), pp. 443-454. International Medical Press

Text AVT-080511-Haupts.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (300kB)

OBJECTIVE

To determine whether genotypic resistance testing leads to selection of more potent drug regimens when compared to regimens based on treatment history only.

DESIGN

Prospective, tertiary care centre-based study.

PATIENTS

One-hundred-and-forty-five HIV-infected adults on stable antiretroviral therapy (ART) for >6 months experiencing virological failure.

METHODS

The physicians' decision-making process when choosing a salvage regimen was prospectively documented: at time of virological failure, on 'failing ART', genotyping was performed and a hypothetical 'clinical expert ART' based upon patient's drug history was documented. Subsequently, data on resistance mutations, rating by a decision support software and drug history were used to define 'genotyping ART'. After discussion with the patient, final treatment, 'new personalized ART' was chosen and prescribed. To compare the relative potency of the four ART regimens in a standardized manner, a resistance score ranging from 1 (best) to 8 (worst) based on drug ranking by decision support software was attributed to each ART regimen. Virological and immunological outcomes were analysed based on the magnitude of the resistance score.

RESULTS

Median follow-up was 1.5 years. In all 145 patients, median resistance scores for the stepwise selected ART regimens were: 'failing ART': 4.5, 'clinical expert ART': 1.8, 'genotyping ART': 1.5 and 'new personalized ART': 2. The latter was 1.5 in patients who effectively switched to 'new personalized ART' (n=89). Lower resistance scores translated into significantly improved virological response after initiation of 'new personalized ART'. In multivariable analysis, lower resistance scores, lower baseline HIV RNA levels and use of novel antiretroviral drugs were associated with the probability of reducing plasma viraemia to <50 copies/ml.

CONCLUSIONS

This study suggests that treatment choices including genotype and decision support software were virologically superior to those based on drug history only.

Interest & Impact

Downloads

1 since deposited on 03 Feb 2021
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item